Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

被引：0

作者：

Ozaki, Shuji ^{[1
]}

Harada, Takeshi ^{[2
]}

Udaka, Kengo ^{[1
]}

Sekimoto, Etsuko ^{[1
]}

Shibata, Hironobu ^{[1
]}

Shigekiyo, Toshio ^{[1
]}

Yagi, Hikaru ^{[1
]}

Okamoto, Yasunobu ^{[2
]}

Sogabe, Kimiko ^{[2
]}

Oura, Masahiro ^{[2
]}

Fujii, Shiro ^{[2
]}

Nakamura, Shingen ^{[2
]}

Miki, Hirokazu ^{[3
]}

Kagawa, Kumiko ^{[2
]}

Abe, Masahiro ^{[2
]}

机构：

[1] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Tokushima, Japan

[2] Tokushima Univ Hosp, Dept Hematol, Tokushima, Tokushima, Japan

[3] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Tokushima, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-115818

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5577

引用

页数：3

共 50 条

[21] Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
Hajek, Roman
Minarik, Jiri
Straub, Jan
Pour, Ludek
Jungova, Alexandra
Berdeja, Jesus G.
Boccadoro, Mario
Brozova, Lucie
Spencer, Andrew
Rhee, Frits van
Vela-Ojeda, Jorge
Thompson, Michael A.
Abonour, Rafat
Chari, Ajai
Cook, Gordon
Costello, Caitlin L.
Davies, Faith E.
Hungria, Vania T. M.
Lee, Hans C.
Leleu, Xavier
Puig, Noemi
Rifkin, Robert M.
Terpos, Evangelos
Usmani, Saad Z.
Weisel, Katja C.
Zonder, Jeffrey A.
Barinova, Magda
Kuhn, Matyas
Silar, Jiri
Capkova, Lenka
Galvez, Kenny
Lu, Jin
Elliott, Jennifer
Stull, Dawn Marie
Ren, Kaili
Maisnar, Vladimir
FUTURE ONCOLOGY, 2021, 17 (19) : 2499 - 2512
[22] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Jiri Minarik
Tomas Pika
Jakub Radocha
Alexandra Jungova
Jan Straub
Tomas Jelinek
Ludek Pour
Petr Pavlicek
Martin Mistrik
Lucie Brozova
Petra Krhovska
Katerina Machalkova
Pavel Jindra
Ivan Spicka
Hana Plonkova
Martin Stork
Jaroslav Bacovsky
Lenka Capkova
Michal Sykora
Petr Kessler
Lukas Stejskal
Adriana Heindorfer
Jana Ullrychova
Tomas Skacel
Vladimir Maisnar
Roman Hajek
BMC Cancer, 21
[23] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Minarik, Jiri
Pika, Tomas
Radocha, Jakub
Jungova, Alexandra
Straub, Jan
Jelinek, Tomas
Pour, Ludek
Pavlicek, Petr
Mistrik, Martin
Brozova, Lucie
Krhovska, Petra
Machalkova, Katerina
Jindra, Pavel
Spicka, Ivan
Plonkova, Hana
Stork, Martin
Bacovsky, Jaroslav
Capkova, Lenka
Sykora, Michal
Kessler, Petr
Stejskal, Lukas
Heindorfer, Adriana
Ullrychova, Jana
Skacel, Tomas
Maisnar, Vladimir
Hajek, Roman
BMC CANCER, 2021, 21 (01)
[24] Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Richardson, PGG
Barlogie, B
Berenson, J
Singhal, S
Jagannath, S
Irwin, D
Rajkumar, SV
Hideshima, T
Xiao, H
Esseltine, D
Schenkein, D
Anderson, KC
BLOOD, 2005, 106 (09) : 2977 - 2981
[25] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
Laubach, J. P.
Mahindra, A.
Mitsiades, C. S.
Schlossman, R. L.
Munshi, N. C.
Ghobrial, I. M.
Carreau, N.
Hideshima, T.
Anderson, K. C.
Richardson, P. G.
LEUKEMIA, 2009, 23 (12) : 2222 - 2232
[26] The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies
Moreau, Philippe
SEMINARS IN HEMATOLOGY, 2012, 49 (03) : S33 - S46
[27] Treatment of relapsed and refractory multiple myeloma in the era of novel agents
van de Donk, Niels W. C. J.
Lokhorst, Henk M.
Dimopoulos, Meletios
Cavo, Michele
Morgan, Gareth
Einsele, Hermann
Kropff, Martin
Schey, Steve
Avet-Loiseau, Herve
Ludwig, Heinz
Goldschmidt, Hartmut
Sonneveld, Pieter
Johnsen, Hans E.
Blade, Joan
San-Miguel, Jesus F.
Palumbo, Antonio
CANCER TREATMENT REVIEWS, 2011, 37 (04) : 266 - 283
[28] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J P Laubach
A Mahindra
C S Mitsiades
R L Schlossman
N C Munshi
I M Ghobrial
N Carreau
T Hideshima
K C Anderson
P G Richardson
Leukemia, 2009, 23 : 2222 - 2232
[29] Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma
Hari, P.
Romanus, D.
Henk, H. J.
Becker, L. K.
Noga, S. J.
Morrison, V. A.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (01) : 45 - 51
[30] Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
Pantani, Lucia
Zamagni, Elena
Zannetti, Beatrice Anna
Pezzi, Annalisa
Tacchetti, Paola
Brioli, Annamaria
Mancuso, Katia
Perrone, Giulia
Rocchi, Serena
Tosi, Patrizia
Cavo, Michele
ANNALS OF HEMATOLOGY, 2014, 93 (01) : 123 - 128

← 1 2 3 4 5 →